文献速递白血病

酪氨酸激酶抑制剂治疗的慢性髓性白血病患者的不良结局:2002-2017年诊断患者的随访,一项全覆盖全国性不可知登记研究

Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.
PubMed 文献 · Am J Hematol · 2022-01-20

这项基于瑞典全国登记数据的队列研究纳入2002-2017年诊断并接受酪氨酸激酶抑制剂(TKI)治疗的1328例慢性期慢性髓性白血病(CML)患者,与匹配对照比较 morbility。中位随访6年,总随访8510人年。在670个分析疾病类别中,患者队列142类风险显著增加,而对照组无任何类别更常见。第二代TKI相比伊马替尼有特定不良事件风险升高。

要点

  • TKI治疗的CML患者相比匹配对照,142个疾病类别风险显著增加。
  • 严重事件IRR升高:急性心肌梗死2.0、心力衰竭2.6、肺炎2.8、不明原因脓毒症3.5。
  • 尼洛替尼相比伊马替尼急性心肌梗死IRR 2.9、慢性缺血性心脏病IRR 2.2。

核心结论

  • 真实世界数据显示,TKI治疗的CML患者相比匹配对照,严重疾病风险显著增加,尤其是第二代TKI。
  • 这种发病率增加是否转化为死亡率增加,从而阻止CML患者达到正常总生存,需进一步探索。

研究设计与样本

  • 大型队列研究,纳入2002-2017年诊断的1328例瑞典CML慢性期患者,接受TKI治疗,与严格匹配的对照个体比较。
  • 利用多个瑞典患者登记处,接近全国完全覆盖,获取数据。
  • 中位随访6年(IQR 3-10),全队列总随访8510人年。

主要发现

  • 在670个分析的疾病类别中,患者队列142类风险显著增加,而对照组无任何类别更常见。
  • 患者严重事件IRR(95%CI):急性心肌梗死2.0(1.5-2.6),心力衰竭2.6(2.2-3.2),肺炎2.8(2.3-3.5),不明原因脓毒症3.5(2.6-4.7)。
  • 队列内分析比较第二代TKI与伊马替尼:尼洛替尼急性心肌梗死IRR 2.9(1.5-5.6),慢性缺血性心脏病IRR 2.2(1.2-3.9)。
  • 达沙替尼胸腔积液IRR 11.6(7.6-17.7),感染并发症如急性上呼吸道感染IRR 3.0(1.4-6.0)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tyrosine kinase inhibitors (TKIs) have profoundly improved the clinical outcome for patients with chronic myeloid leukemia (CML), but their overall survival is still subnormal and the treatment is associated with adverse events. In a large cohort-study, we assessed the morbidity in 1328 Swedish CML chronic phase patients diagnosed 2002-2017 and treated with TKIs, as compared to that in carefully matched control individuals. Several Swedish patient registers with near-complete nationwide coverage were utilized for data acquisition. Median follow-up was 6 (IQR, 3-10) years with a total follow-up of 8510 person-years for the full cohort. Among 670 analyzed disease categories, the patient cohort showed a significantly increased risk in 142 while, strikingly, no category was more common in controls. Increased incidence rate ratios/IRR (95% CI) for more severe events among patients included acute myocardial infarction (AMI) 2.0 (1.5-2.6), heart failure 2.6 (2.2-3.2), pneumonia 2.8 (2.3-3.5), and unspecified sepsis 3.5 (2.6-4.7). When comparing patients on 2nd generation TKIs vs. imatinib in a within-cohort analysis, nilotinib generated elevated IRRs for AMI (2.9; 1.5-5.6) and chronic ischemic heart disease (2.2; 1.2-3.9), dasatinib for pleural effusion (11.6; 7.6-17.7) and infectious complications, for example, acute upper respiratory infections (3.0; 1.4-6.0). Our extensive real-world data reveal significant risk increases of severe morbidity in TKI-treated CML patients, as compared to matched controls, particularly for 2nd generation TKIs. Whether this increased morbidity may also translate into increased mortality, thus preventing CML patients to achieve a normalized overall survival, needs to be further explored.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Dahlén T, Edgren G, Ljungman P, et al. Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study. Am J Hematol. 2022. PMID: 35015312. doi:10.1002/ajh.26463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。